This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- Future Directions in Molecular Imaging of Neurodegenerative Disorders
- MRI-Based Attenuation Correction for PET/MRI Using Multiphase Level-Set Method
- Segmentation-Based MR Attenuation Correction Including Bones Also Affects Quantitation in Brain Studies: An Initial Result of 18F-FP-CIT PET/MR for Patients with Parkinsonism
- Quantification of Dopamine Transporter in Human Brain Using PET with 18F-FE-PE2I
- Pancreatic Imaging with 11C-Dihydrotetrabenazine PET: A Perspective
- Pharmacological Characterization of (E)-N-(4-Fluorobut-2-enyl)-2beta-carbomethoxy-3beta-(4'-tolyl)nortropane (LBT-999) as a Highly Promising Fluorinated Ligand for the Dopamine Transporter
- Initial Human PET Imaging Studies with the Dopamine Transporter Ligand 18F-FECNT
- Dosimetry of the Dopamine Transporter Radioligand 18F-FPCIT in Human Subjects